ClinicalTrials.gov
public full text
Public Domain
Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI
The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza#1059414
- Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old#849220
- Effectiveness of a Nasal Spray on Viral Respiratory Infections#1307232
- A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A#1231125
- MDL-001: an Oral, Direct-Acting Universal Antiviral for Influenza-Like Illness (ILI) and Chronic Hepatitis#429563
Record · ID 1349721
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive